Oncotelic appoints CMO Fatih Uckun and CRO Seymour Fein effective May 1, 2022

Oncotelic Therapeutics, Inc.

Fatih Uckun appointed Consulting CMO; $504k/year salary, 70% time commitment.
Seymour Fein appointed Consulting Chief Regulatory Officer; $180k/year, 10% time.
Both to lead OT-101 registration trials for DIPG and pancreatic cancer under joint venture.
Uckun previously CMO at Reven, Ares, Aptevo; Fein has 35+ years and 20+ FDA approvals.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Fatih Uckun

Consulting Chief Medical Officer

OTLC · Oncotelic Therapeutics, Inc.

Effective: 2022-05-01
Filed: May 6, 2022, 7:59 PM ET

On May 1, 2022, Oncotelic Therapeutics, Inc. (the “ Company ”) appointed Fatih Uckun, M.D., Ph.D. as its Consulting Chief Medical Officer for the Company.

Appointed

Seymour Fein

Consulting Chief Regulatory Officer

OTLC · Oncotelic Therapeutics, Inc.

Effective: 2022-05-01
Filed: May 6, 2022, 7:59 PM ET

In addition, on May 1, 2022, the Company appointed Dr. Seymour Fein as its Consulting Chief Regulatory Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Fatih Uckun was appointed as Consulting Chief Medical Officer at Oncotelic Therapeutics, Inc..

Action: appointed
Role: Consulting Chief Medical Officer

Exact text from the filing

On May 1, 2022, Oncotelic Therapeutics, Inc. (the “ Company ”) appointed Fatih Uckun, M.D., Ph.D. as its Consulting Chief Medical Officer for the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Seymour Fein was appointed as Consulting Chief Regulatory Officer at Oncotelic Therapeutics, Inc..

Action: appointed
Role: Consulting Chief Regulatory Officer

Exact text from the filing

In addition, on May 1, 2022, the Company appointed Dr. Seymour Fein as its Consulting Chief Regulatory Officer.

View on SEC.gov

Oncotelic Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-012308

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.